Oncoloxía médica

2023

1. 25 Años del asunto Di Bella: ¿qué enseñanzas éticas nos deja?

   Cuadernos de bioética, Vol. 34, Núm. 112, pp. 269-278

2. A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 2911-2925

3. A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide

   Prostate, Vol. 83, Núm. 4, pp. 376-384

4. A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative

   Supportive Care in Cancer, Vol. 31, Núm. 12

5. A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients

   Biomedicine and Pharmacotherapy, Vol. 159

6. Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study

   ERJ Open Research, Vol. 9, Núm. 6

7. Adjuvant dabrafenib and trametinib for patients with resected BRAF -mutated melanoma: DESCRIBE-AD real-world retrospective observational study

   Melanoma research, Vol. 33, Núm. 5, pp. 388-397

8. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial

   The Lancet, Vol. 401, Núm. 10379, pp. 821-832

9. Agitación psicomotriz y conducta agresiva en urgencias pediátricas

   Revista de Psiquiatría Infanto-Juvenil, Vol. 41, Núm. 1, pp. 4-12

10. Ascites-Derived Organoids to Depict Platinum Resistance in Gynaecological Serous Carcinomas

    International Journal of Molecular Sciences, Vol. 24, Núm. 17

11. Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials

    Clinical Colorectal Cancer, Vol. 22, Núm. 2, pp. 222-230

12. Bioinformatics analysis and single-cell RNA sequencing: elucidating the ubiquitination pathways and key enzymes in lung adenocarcinoma

    Journal of Thoracic Disease, Vol. 15, Núm. 7, pp. 3885-3907

13. Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer

    Thrombosis Research, Vol. 232, pp. 133-137

14. Can Oncologists Prompt Patient Prognostic Awareness to Enhance Decision-Making? Data From the NEOetic Study

    Oncologist, Vol. 28, Núm. 11, pp. 986-995

15. Cancer-associated fibroblasts actively compress cancer cells and modulate mechanotransduction

    Nature communications, Vol. 14, Núm. 1, pp. 6966

16. Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer

    Expert Review of Anticancer Therapy, Vol. 23, Núm. 1, pp. 95-106

17. Clinical, molecular, and immune correlates of the Immunotherapy Response Score in patients with advanced urothelial carcinoma under atezolizumab monotherapy: analysis of the phase II IMvigor210 trial

    ESMO Open, Vol. 8, Núm. 4

18. Clinicopathological Profiles Associated with Discordant RAS Mutational Status between Liquid and Tissue Biopsies in a Real-World Cohort of Metastatic Colorectal Cancer

    Cancers, Vol. 15, Núm. 14

19. Comparative evaluation of PD-L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non-small cell lung cancer patients

    Molecular Oncology, Vol. 17, Núm. 5, pp. 737-746

20. Coping strategies as mediators of uncertainty and psychological distress in patients with advanced cancer

    Psycho-Oncology, Vol. 32, Núm. 11, pp. 1694-1701